Cat. No. | Product name | CAS No. |
DC65498 |
hCAII-IN-9
Featured
hCAII-IN-9 is a potent carbonic anhydrase inhibitor |
2878477-18-8 |
DC65499 |
hCAII-IN-8
Featured
hCAII-IN-8, an amide, is a highly selective carbonic anhydrase (CA) inhibitor with an IC50 value of 0.18 μM against hCA II[1]. |
952306-80-8 |
DC65500 |
GW6340
Featured
GW6340 is an intestinal-specific LXR agonist. |
405910-78-3 |
DC65501 |
GFP16
Featured
GFP16 is a low affinity antiprion compound. |
749212-56-4 |
DC65502 |
BI-2865
Featured
BI-2865 is a none-covalent pan-KRAS Inhibitor. BI-2865 blocked nucleotide exchange to prevent the activation of wild-type KRAS and a broad range of KRAS mutants, including G12A/C/D/F/V/S, G13C/D, V14I, L19F, Q22K, D33E, Q61H, K117N and A146V/T. Inhibition of downstream signalling and proliferation was restricted to cancer cells harbouring mutant KRAS, and drug treatment suppressed KRAS mutant tumour growth in mice, without having a detrimental effect on animal weight. |
2937327-93-8 |
DC65503 |
KIF18A-IN-3
Featured
KIF18A-IN-3 is a potent KIF18A inhibitor (IC50=61 nM). KIF18A-IN-3 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-3 can be used for researching cancer[1]. |
2600577-49-7 |
DC65504 |
Skp2 inhibitor 1
Featured
Skp2 inhibitor 1 (compound 14i) is a potent and selective Skp2 inhibitor |
2760612-63-1 |
DC65505 |
PRMT6-IN-3
Featured
PRMT6-IN-3 (compound 25) is a selective PRMT6 inhibitor |
2890765-10-1 |
DC65506 |
PARP10-IN-2
Featured
PARP10-IN-2 is a potent mono‐ADP‐ribosyltransferase PARP10 inhibitor with an IC50 of 3.64 μM for human PARP10. PARP10-IN-2 reveals potent inhibition on PARP2 and PARP15 with IC50s of 27 μM and 11 μM for human PARP2 and human PARP15, respectively[1]. |
1042780-52-8 |
DC65507 |
PHGDH-IN-3
Featured
PHGDH-IN-3 is an orally active phosphoglycerate dehydrogenase (PHGDH) inhibitor. PHGDH-IN-3 inhibits PHGDH with an IC50 value of 2.8 μM. PHGDH-IN-3 can be used for the research of cancer[1]. |
2893778-31-7 |
DC65508 |
MyD88-IN-1
Featured
MyD88-IN-1 is a potent MyD88 inhibitor. |
2911609-80-6 |
DC65509 |
TNF-α-IN-9
Featured
TNF-α-IN-9 (compound 48) is a analog of NDM-1 inhibitor-3 |
2054199-25-4 |
DC65510 |
Antibacterial agent 132
Featured
Antibacterial agent 132 has anticandidal effects against C. parapsilosis (ATCC 22019) and C. krusei (ATCC 6258) |
|
DC65511 |
Antibacterial agent 133
Featured
Antibacterial agent 133 (4l) is an antimicrobial agent |
|
DC65512 |
WDR5-IN-6
Featured
WDR5-IN-6 is a WDR5 inhibitor. |
326901-92-2 |
DC65513 |
HYNIC-FAPI-04
Featured
HYNIC-FAPI-04 is a useful ligand for making [99mTc]Tc-HYNIC-FAPI-04. In vitro experiments, the results indicated that [99mTc]Tc-HYNIC-FAPI-04 showed binding properties, and inhibited the migration of tumor cells. The [99mTc]Tc-HYNIC-FAPI will be a promising SPECT/CT imaging probe. |
|
DC65514 |
NOTA-FAPI-46
Featured
NOTA-FAPI-46 is an analogue of FAPI-46 (MedKoo Cat#207189). NOTA-FAPI-46 is useful in the diagnosis or treatment of a disease characterized by overexpression of fibroblast activation protein (FAP). NOTA-FAPI-46 can be used as a PET tracer for detection of diseases or disorders related to fibroblast activation protein. |
|
DC65515 |
HYNIC-PSMA
Featured
HYNIC-PSMA is a PSMA based ligand, which can bind radio-active metal ion and used as a tumor-imaging agent in prostate cancer. 99mTc-HYNIC-PSMA is a novel technetium-99m-labeled small-molecule inhibitor of prostate-specific membrane antigen (PSMA) for detection of prostate cancer. 99mTc-HYNIC-PSMA showed high tracer uptake (with a tumor-to-background ratio of 9.42 ± 2.62) in the malignant lesions of PCa patients, making it a promising radiopharmaceutical imaging method for site-specific management of PCa. |
|
DC65516 |
PSMA-BCH
Featured
PSMA-BCH also known as NOTA-PSMA, is a PSMA- NOTA-conjugated precursor. 68Ga-PSMA-BCH can be used for prostate cancer imaging. Al18F-PSMA-BCH can be used for prostate cancer imaging as a novel 18F PET radiotracer. 64Cu-PSMA-BCH is a new radiotracer for delayed PET imaging of prostate cancer. 64Cu-PSMA-BCH was PSMA specific and showed high stability in vivo with lower uptake in liver than 64Cu-PSMA-617. Biodistribution in mice and PCa patients showed similar profile compared with other PSMA ligands and it was safe with moderate effective dosimetry. |
1703768-73-3 |
DC65517 |
PSMA-I&T
Featured
PSMA-I&T is a PSMA-based radioligand. [177Lu]Lu-PSMA I&T can be uused for potential treatment of metastatic castration-resistant prostate cancer. 67 Ga-PSMA I&T can be used for Radioguided Surgery of Lymph Node Metastases With Biochemical Recurrence of Prostate Cancer |
2192281-54-0 |
DC89101 |
C12-4 (C12-494,Lipid A-4)
Featured
C12-4 (C12-494,Lipid A-4) is a branched-chain ionizable cationic lipidoid that has been used in the formation of lipid nanoparticles (LNPs) for the delivery of mRNA. LNPs containing lipid A4 and encapsulating an mRNA reporter accumulate in the uterus, placenta, and ovaries, as well as to the spleen and liver, in pregnant mouse dams unlike LNPs containing the branched-chain ionizable cationic lipidoid C12-200, which primarily accumulate in the liver. Intravenous administration of LNPs containing lipid A4 and encapsulating mRNA encoding VEGF increase placental VEGFR1 levels and mean fetal blood vessel area without inducing liver damage in pregnant mouse dams. |
2639634-71-0 |
DC60484 |
Clovibactin
Featured
Clovibactin is an antibiotic isolated from uncultured soil bacteria. Clovibactin efficiently kills drug-resistant Gram-positive bacterial pathogens without detectable resistance. Clovibactin blocks cell wall synthesis by targeting pyrophosphate of multiple essential peptidoglycan precursors. |
2247194-77-8 |